{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:45:35Z","timestamp":1788561935475,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.dld.2023.11.025","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T04:37:07Z","timestamp":1702787827000},"page":"1014-1020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts"],"prefix":"10.1016","volume":"56","author":[{"given":"Maria","family":"Cappello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Consalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-8645","authenticated-orcid":false,"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariabeatrice","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2894","authenticated-orcid":false,"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-700X","authenticated-orcid":false,"given":"Laura","family":"Obici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dld.2023.11.025_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.dld.2023.11.025_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care","volume":"16","author":"Luigetti","year":"2020","journal-title":"TCRM"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","article-title":"Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights","volume":"7","author":"Koike","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.dld.2023.11.025_bib0004","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.dld.2023.11.025_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy: ATTR-FAP global prevalence","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.dld.2023.11.025_bib0006","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MEG.0000000000002030","article-title":"Recommendations for the diagnosis and management of transthyretin amyloidosis with gastrointestinal manifestations","volume":"33","author":"Nakov","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2023.11.025_bib0007","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13506129.2020.1794807","article-title":"ATTRv amyloidosis Italian Registry: clinical and epidemiological data","volume":"27","author":"Russo","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.dld.2023.11.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.03.063","article-title":"Prevalence of transthyretin-related amyloidosis in Tuscany: data from the regional population-based registry","author":"Cappelli","year":"2023","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.dld.2023.11.025_bib0009","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2023.11.025_bib0012","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14656566.2020.1836159","article-title":"Advances in pharmacotherapy for cardiac amyloidosis","volume":"22","author":"Spoladore","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ejhf.1695","article-title":"Emerging therapies in transthyretin amyloidosis \u2013 a new wave of hope after years of stagnancy?","volume":"22","author":"M\u00fcller","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.dld.2023.11.025_bib0014","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/brainsci11050545","article-title":"Use of drugs for ATTRv amyloidosis in the real world: how therapy is changing survival in a non-endemic area","volume":"11","author":"Russo","year":"2021","journal-title":"Brain Sci"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus","volume":"15","author":"Grandis","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0016","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13023-021-01960-9","article-title":"Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression","volume":"16","author":"Adams","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.dld.2023.11.025_bib0017","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/13506129.2021.1917357","article-title":"Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation","volume":"28","author":"Pastorelli","year":"2021","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40119-021-00226-6","article-title":"Phenotypic differences of Glu89Gln genotype in ATTR amyloidosis from endemic loci: update from THAOS","volume":"10","author":"Gentile","year":"2021","journal-title":"Cardiol Ther"},{"issue":"6","key":"10.1016\/j.dld.2023.11.025_bib0019","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12265-018-9859-0","article-title":"Amyloid cardiomyopathy in the rare transthyretin Tyr78Phe mutation","volume":"12","author":"Tini","year":"2019","journal-title":"J Cardiovasc Trans Res"},{"key":"10.1016\/j.dld.2023.11.025_bib0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"S1","key":"10.1016\/j.dld.2023.11.025_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis","volume":"29","author":"Obici","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.dld.2023.11.025_bib0022","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis-common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.dld.2023.11.025_bib0023","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15403\/jgld-2474","article-title":"Gastrointestinal manifestations in hereditary transthyretin amyloidosis: a single-centre experience","volume":"29","author":"Luigetti","year":"2020","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.dld.2023.11.025_bib0024","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\"Red-flag\" symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst"},{"issue":"S1","key":"10.1016\/j.dld.2023.11.025_bib0025","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.dld.2023.11.025_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.11.025_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5009\/gnl16055","article-title":"Functional dyspepsia: advances in diagnosis and therapy","volume":"11","author":"Talley","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2023.11.025_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2020.06.029","article-title":"Transthyretin amyloidosis: testing strategies and model for center of excellence support","volume":"509","author":"Nakov","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.dld.2023.11.025_bib0029","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.22085","article-title":"A rare case of gastrointestinal amyloidosis presenting as dysphagia","author":"Ailawadi","year":"2022","journal-title":"Cureus [Internet]"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o","year":"2007","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.dld.2023.11.025_bib0031","doi-asserted-by":"crossref","first-page":"421","DOI":"10.15403\/jgld-362","article-title":"Gastrointestinal manifestations in hereditary transthyretin amyloidosis associated with Glu89Gln mutation","volume":"28","author":"Nakov","year":"2019","journal-title":"JGLD"},{"issue":"Supplement 2","key":"10.1016\/j.dld.2023.11.025_bib0032","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/S1590-8658(23)00426-7","article-title":"09.8 From bowel ultrasound to a diagnosis of hereditary transthyretin amyloidosis","volume":"55","author":"Toppeta","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17474124.2018.1397511","article-title":"Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single center experience over 40 years","volume":"12","author":"Wixner","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.11.025_bib0034","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13506129.2019.1582514","article-title":"Self-reported gastrointestinal symptoms are more common in liver transplanted transthyretin amyloidosis patients than in healthy controls and in patients transplanted for end-stage liver disease","volume":"26","author":"Marberg","year":"2019","journal-title":"Amyloid"},{"issue":"8","key":"10.1016\/j.dld.2023.11.025_bib0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4253\/wjge.v3.i8.157","article-title":"Endoscopic and histopathological features of gastrointestinal amyloidosis","volume":"3","author":"Hokama","year":"2011","journal-title":"WJGE"},{"issue":"12","key":"10.1016\/j.dld.2023.11.025_bib0036","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3748\/wjg.v27.i12.1132","article-title":"Primary localized gastric amyloidosis: a scoping review of the literature from clinical presentations to prognosis","volume":"27","author":"Lin","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0037","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","article-title":"Multidisciplinary approaches for transthyretin amyloidosis","volume":"10","author":"Koike","year":"2021","journal-title":"Cardiol Ther"},{"issue":"3","key":"10.1016\/j.dld.2023.11.025_bib0038","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jgh.13996","article-title":"Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views","volume":"33","author":"Iida","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0039","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2017.1324418","article-title":"Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis","volume":"24","author":"Brown","year":"2017","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.dld.2023.11.025_bib0040","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0041","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dld.2022.11.015","volume":"55","author":"Barbara","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.dld.2023.11.025_bib0042","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ueg2.12259","article-title":"Functional bowel disorders with diarrhoea: clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility","volume":"10","author":"Savarino","year":"2022","journal-title":"United European Gastroenterol J"},{"issue":"11","key":"10.1016\/j.dld.2023.11.025_bib0043","doi-asserted-by":"crossref","first-page":"e19509","DOI":"10.1097\/MD.0000000000019509","article-title":"Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations","volume":"99","author":"Nakov","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.dld.2023.11.025_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10286-018-0514-2","article-title":"Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis)","volume":"29","author":"Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"issue":"2","key":"10.1016\/j.dld.2023.11.025_bib0046","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jns.12381","article-title":"Acquired and inherited amyloidosis: knowledge driving patients' care","volume":"25","author":"Obici","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"10.1016\/j.dld.2023.11.025_bib0047","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.dld.2023.11.025_bib0048","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012395.pub2","article-title":"Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Neuromuscular Group, curatore","author":"Magrinelli","year":"2020","journal-title":"Cochrane Database System Rev [Internet]"},{"issue":"4","key":"10.1016\/j.dld.2023.11.025_bib0049","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA Drugs and RNA targets for small molecules: principles, progress, and challenges. Touyz RM, curatore","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.dld.2023.11.025_bib0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11912-023-01397-2","article-title":"Emerging therapies for transthyretin amyloidosis","volume":"25","author":"Tsoi","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.dld.2023.11.025_bib0051","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00415-019-09602-8","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Gonz\u00e1lez-Duarte","year":"2020","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.dld.2023.11.025_bib0052","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40120-023-00522-4","article-title":"Impact of vutrisiran on quality of life and physical function in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"12","author":"Obici","year":"2023","journal-title":"Neurol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2023.11.025_bib0053","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10286-019-00626-8","article-title":"Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system","volume":"29","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Clin Auton Res"},{"issue":"8","key":"10.1016\/j.dld.2023.11.025_bib0054","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.14309\/ajg.0000000000001874","article-title":"ACG clinical guideline: gastroparesis","volume":"117","author":"Camilleri","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2023.11.025_bib0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ueg2.12060","article-title":"United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis","volume":"9","author":"Schol","year":"2021","journal-title":"United European Gastroenterol J"},{"issue":"Suppl 1(Suppl 1)","key":"10.1016\/j.dld.2023.11.025_bib0056","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"s2","key":"10.1016\/j.dld.2023.11.025_bib0057","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.3233\/JND-150091","article-title":"Transthyretin-related familial amyloid polyneuropathy (TTR-FAP): a single-center experience in Sicily, an Italian endemic area","volume":"2","author":"Mazzeo","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.dld.2023.11.025_bib0058","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S1590-8658(22)00305-X","article-title":"OC.06.4 Gastrointestinal involvement in hereditary transthyretin amyloidosis: the role of gastroenterologists in early diagnosis of a progressive but now potentially curable disease","volume":"54","author":"Brinch","year":"2022","journal-title":"Dig Liver Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823010630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823010630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:43:03Z","timestamp":1728909783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823010630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1590865823010630"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.11.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}